Spectrum Pharma (SPPI) Misses Q4 EPS by 9c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Spectrum Pharmaceuticals (SPPI) PT Lowered to $42 at H.C. Wainwright
March 1, 2019 9:02 AM ESTH.C. Wainwright analyst Edward White lowered the price target on Spectrum Pharmaceuticals (NASDAQ: SPPI) to $42.00 (from $43.00) while maintaining a Buy rating.
The analyst commented, "Spectrum reported 4Q18 non-GAAP EPS of ($0.30), versus our estimate of ($0.18) and the consensus non-GAAP estimate of ($0.21). Revenues in the quarter were $29.4... More
